Gamida Cell ltd

Los Angeles, California

OncologyPhase III

What changed

Phase III trial registered: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

3w agoTrial registeredJun 22, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Jul 8, 2020
Hematological Malignancies · COMPLETED · sponsor: Gamida Cell ltd · Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
ClinicalTrials.gov · NCT04260698 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 16, 2016
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia · COMPLETED · sponsor: Gamida Cell ltd · Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
ClinicalTrials.gov · NCT02730299 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.99{"reasons":["name similarity 100%","semantic similarity 81%","shared principal investigator / founder","same city"]}
new_entity links the trial record at 0.12{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
3w agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
4mo agoTrial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

PHASE3 registered